Erick Gamelin's most recent trade in Acrivon Therapeutics Inc was a trade of 94,946 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Acrivon Therapeutics Inc | Erick Gamelin | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2026 | 94,946 | 94,946 | - | - | Stock Option (Right to Buy) | |
| Acrivon Therapeutics Inc | Erick Gamelin | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.63 per share. | 14 Feb 2026 | 471 | 14,812 | - | 1.6 | 768 | Common Stock |
| Acrivon Therapeutics Inc | Erick Gamelin | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.24 per share. | 14 Nov 2025 | 403 | 15,283 | - | 2.2 | 903 | Common Stock |
| Acrivon Therapeutics Inc | Erick Gamelin | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.39 per share. | 14 Aug 2025 | 403 | 15,686 | - | 1.4 | 560 | Common Stock |
| Acrivon Therapeutics Inc | Erick Gamelin | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.14 per share. | 14 May 2025 | 403 | 16,089 | - | 1.1 | 459 | Common Stock |
| Acrivon Therapeutics Inc | Erick Gamelin | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 78,078 | 78,078 | - | - | Stock Option (Right to Buy) | |
| Acrivon Therapeutics Inc | Erick Gamelin | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.42 per share. | 14 Feb 2025 | 469 | 16,492 | - | 5.4 | 2,542 | Common Stock |
| Acrivon Therapeutics Inc | Erick Gamelin | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.92 per share. | 14 Nov 2024 | 402 | 16,961 | - | 7.9 | 3,184 | Common Stock |
| Acrivon Therapeutics Inc | Erick Gamelin | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.02 per share. | 14 Aug 2024 | 402 | 17,363 | - | 7.0 | 2,822 | Common Stock |
| Acrivon Therapeutics Inc | Erick Gamelin | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.36 per share. | 14 May 2024 | 402 | 17,765 | - | 8.4 | 3,361 | Common Stock |
| Acrivon Therapeutics Inc | Gamelin Erick | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 45,045 | 45,045 | - | - | Stock Option (Right to Buy) | |
| Acrivon Therapeutics Inc | Erick Gamelin | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.40 per share. | 14 Feb 2024 | 468 | 18,167 | - | 3.4 | 1,591 | Common Stock |
| Acrivon Therapeutics Inc | Erick Gamelin | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 60,090 | 60,090 | - | - | Stock Option (Right to Buy) | |
| Acrivon Therapeutics Inc | Erick Gamelin | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 20,030 | 20,030 | - | 0 | Common Stock |